BioMark Diagnostics appoints James Lavender to board of directors

BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) announced the appointment of James Lavender to its board of directors, effective following resolutions accepted at the company's annual general meeting held December 22, 2025.

Lavender and his investment group participated as major investors in BioMark's financing completed in March 2025. The Vancouver-based company develops liquid biopsy technologies for early cancer detection.

Lavender brings software development and enterprise sales experience from technology companies, with experience in scaling data-driven platforms. He has worked on expanding BioMark's use of artificial intelligence and machine learning to enhance clinical performance and scalability of metabolomics-based oncology diagnostics.

"We are very fortunate to have James on our board as both a strategic investor and an operator who understands how to build technology-driven, scalable businesses," said Rashid Ahmed Bux, president and CEO of BioMark. "His network and experience in software, AI, and U.S. market development will be highly valuable as we move into commercialization, finalize our certifications, and grow our lab services footprint."

BioMark stated that Lavender has been involved in opening channels with state-level organizations and strategic investment groups in the United States as the company works toward U.S. market entry.

The company's technology uses blood draws to detect cancer-associated biomarkers for earlier diagnosis. The technology can also measure treatment response and potentially monitor cancer survivors.

You May Also Be Interested In

• Apple suing OpenAI over alleged misappropriation of trade secrets
• GuideAI Health hires firms for marketing and investor outreach
• Ideal Power (IPWR) files $75M mixed shelf